Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant

Plus, news about Ori­on, Stal­i­cla, Cyra­no Ther­a­peu­tics and In­stil Bio:

Jen­nifer Doud­na’s lat­est ven­ture: Her lab pub­lished a study Thurs­day in Na­ture Biotech­nol­o­gy de­tail­ing how an­ti­body frag­ments can be used to tar­get virus-like par­ti­cles with gene edit­ing ma­chin­ery to T cells. The fine print shows that Doud­na and the study’s first au­thor, Jen­ny Hamil­ton, co-found­ed Aza­lea Ther­a­peu­tics, a ge­net­ic med­i­cine de­liv­ery start­up. Aza­lea has raised $10 mil­lion, ac­cord­ing to a Forbes pro­file of found­ing sci­en­tist Con­nor Tsuchi­da. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.